Abstract 463P
Background
This study sought to understand the treatment landscape for patients with HER2−, locally advanced (LA) unresectable or metastatic gastric/gastroesophageal junction (mG/GEJ) cancer in real-world settings.
Methods
The study was conducted from 20 September 2022 to 11 April 2023 and is based on the Adelphi Real World Disease Specific Programme™, a patient record–based survey of physicians who treat ≥5 patients with LA unresectable or mG/GEJ cancer per month in France, Germany, Italy, Spain, the UK, and Canada. Physicians reported patient demographics, biomarker testing, and treatment patterns. Patients reported on quality of life. Data were analyzed descriptively.
Results
Data were reported by 233 physicians on 1904 patients. Of 1764 patients with G/GEJ adenocarcinoma, 1542 were tested for HER2, and of those, 1096 (71%) were HER2−. The mean (SD) age of HER2− patients was 66.2 (8.8) years and most patients had de novo disease (89%). At time of data collection, about 62%, 36%, and 1% of patients with HER2− disease were receiving first-line (1L), second-line (2L), and third-line (3L) therapy, respectively. The most common 1L chemotherapy regimen among HER2− patients (n=1096) was fluorouracil + oxaliplatin ± leucovorin (41%). The most influential factor in selection of 1L and 2L therapy was chance of progression-free survival; selection of 3L therapy was most influenced by adverse event profile. Besides HER2, common biomarker tests included CPI/CPS-related testing (PD-L1 and/or PD-1; 70%) and MSI/MMRd (57%). The mean (SD) time from start of 1L therapy to end of 1L therapy due to disease progression was 6.4 (3.48) months for 2L patients and 5.1 (2.34) months for 3L patients. The mean (SD) overall EQ-5D-5L VAS score of HER2− patients was 61.31 (16.56); the mean EQ-5D-5L utility score for 1L patients ranged from 0.7 to 0.9 in France, Germany, Spain, and the UK.
Conclusions
Most patients were treated based on the ESMO and NCCN guidelines valid at the time of treatment. This study can be used to inform and interpret future research.
Editorial acknowledgement
Medical writing/editorial support was provided by Stevin Joseph, PharmD, Pamela Barendt, PhD, and Cheryl Casterline, MA, from Peloton Advantage, LLC, an OPEN Health company, and funded by the study sponsor.
Legal entity responsible for the study
Adelphi Real World.
Funding
Astellas Pharma, Inc.
Disclosure
F. Lordick: Financial Interests, Personal, Advisory Board: Amgen, Astellas, BMS, Bayer, BeiGene, Eli Lilly, MSD, Novartis, Roche, Daiichi Sankyo, PAGE; Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Deutscher Ärzteverlag, Eli Lilly, Imedex, Incyte, Iomedico, MSD, MedUpdate, Medscape, Merck Serono, Roche, Servier, Springer-Nature, StreamedUp!, Daiichi Sankyo, Novartis, Art Tempi; Financial Interests, Personal, Expert Testimony: BioNTech, Elsevier; Financial Interests, Institutional, Research Grant: BMS, Gilead. K. Lewis: Non-Financial Interests, Institutional, Full or part-time Employment, Currently employed by Adelphi Real World. This study was undertaken by Adelphi Real World as part of an independent survey, entitled the “Adelphi Real World Advanced Gastric Cancer DSP.” The DSP is a wholly owned Adelphi Real World product. Astellas was one of multiple subscribers to the DSP: Adelphi Real World. A. Lambert: Non-Financial Interests, Institutional, Full or part-time Employment, currently employed by Adelphi Real World. This study was undertaken by Adelphi Real World as part of an independent survey, entitled the “Adelphi Real World Advanced Gastric Cancer DSP.” The DSP is a wholly owned Adelphi Real World product. Astellas was one of multiple subscribers to the DSP: Adelphi Real World. G. Thomason: Non-Financial Interests, Institutional, Full or part-time Employment, currently employed by Adelphi Real World. This study was undertaken by Adelphi Real World as part of an independent survey, entitled the “Adelphi Real World Advanced Gastric Cancer DSP.” The DSP is a wholly owned Adelphi Real World product. Astellas was one of multiple subscribers to the DSP: Adelphi Real World. E. Brown: Non-Financial Interests, Institutional, Full or part-time Employment, currently employed by Adelphi Real World. This study was undertaken by Adelphi Real World as part of an independent survey, entitled the “Adelphi Real World Advanced Gastric Cancer DSP.” The DSP is a wholly owned Adelphi Real World product. Astellas was one of multiple subscribers to the DSP: Adelphi Real World. C. Streutker: Financial Interests, Personal, Invited Speaker, Payment to me, honoraria for presentation: Astellas, Merck; Financial Interests, Personal, Advisory Board, Payment to me, Advisory Board: Boehringer Ingelheim, Merck. F. Rivera Herrero: Financial Interests, Personal, Invited Speaker: Roche, MSD, BMS, Servier, Astellas, Amgen, Merck; Financial Interests, Personal, Advisory Board: MSD, BMS, Servier, Astellas, Amgen, AstraZeneca; Financial Interests, Institutional, Invited Speaker: AstraZeneca, MSD, Novartis, Seagen, OBT, Inspirna. A. Chilelli: Financial Interests, Institutional, Invited Speaker, Support for attending meetings and/or travel: Astellas. All other authors have declared no conflicts of interest.